February 18, 2025
BURLINGTON, Ontario – February 18, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $5,000,000 of gross proceeds, consisting of up to 20,833,333 common shares...
January 28, 2025
BURLINGTON, ON – January 28, 2025 – Rapid Dose Therapeutics Corp. (RDT) (CSE: DOSE), a Canadian biotechnology company working with an international company in oral nicotine products, is pleased to announce the expansion of their collaboration through the continuation of the exclusive pre-commercialization agreement. This...
January 27, 2025
BURLINGTON, Ontario – January 23, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated December 9, 2024 (the “Initial Press Release”), announcing a proposed debt settlement (the “Shares for Debt Transaction”) with certain...
January 16, 2025
BURLINGTON, Ontario – January 15, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has completed its previously announced shares for debt transaction to issue common shares (the “Debt Shares”) to its non-management directors (the “Directors”)...
January 7, 2025
BURLINGTON, Ontario – January 7, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), and consistent with prior quarters, the Company...
December 24, 2024
BURLINGTON, Ontario – December 23, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that it has agreed with its non-management directors (the “Directors”) to issue common shares (the “Debt Shares”) to such Directors in exchange for the cancellation of director...
December 10, 2024
BURLINGTON, Ontario – December 9, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $6,000,000 of gross proceeds, consisting of up to 24,000,000 units (the...
December 5, 2024
BURLINGTON, Ontario – December 5, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company, is pleased to announce that it has filed a patent application for its Lidocaine Oral Thin Film Strip, with the Canadian Intellectual Property Office...
October 30, 2024
BURLINGTON, Ontario – October 30, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that it has closed a second and final tranche of its previously announced equity private placement financing (the “Financing”) for aggregate gross proceeds of...
October 1, 2024
BURLINGTON, Ontario – October 1, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...